Page last updated: 2024-08-25

rosiglitazone and Diabetic Angiopathies

rosiglitazone has been researched along with Diabetic Angiopathies in 62 studies

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's48 (77.42)29.6817
2010's13 (20.97)24.3611
2020's1 (1.61)2.80

Authors

AuthorsStudies
Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM1
Duan, Y; Fu, X; Gao, H; Liu, Y; Xie, C; Xie, H; Yuan, H; Zhou, M1
Argraves, WS; Cangemi, C; Christensen, MM; Gram, J; Grodum, E; Henriksen, JE; Rasmussen, LM; Skov, V; Sørensen, D1
McCarthy, M1
Ciaraldi, TP; Samad, F; Wang, J1
Lehmann, DF; Lohray, BB1
Furberg, CD; Singh, S1
Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A1
Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ1
Abdullah, SM; Ayers, CR; McGavock, JM; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS1
Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A1
Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS1
Krentz, A1
Albert, JM; Bailie, GR; Blayney, MJ; Goodkin, DA; Pisoni, RL; Port, FK; Ramirez, SP; Tentori, F; Wolfe, RA; Young, EW1
Lebovitz, HE1
Barnett, AH1
Simon, D1
Fisher, M1
Booth, A; Konstantinidis, A; Lambley, RG; Vahdani, K1
Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR1
Guo, X; Karathanasis, SK; Kassab, GS; Lu, X; Onyia, JE; Peterson, RG; Zimmerman, KM1
Abdullah, SM; Ayers, CR; de Lemos, JA; Drazner, MH; Khera, A; McGavock, J; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS1
Bloomgarden, Z1
Chilton, RJ; Schernthaner, G1
Gautier, JF; Lesven, S; Maréchaud, R1
Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW1
Wilding, JP1
Aubert, JP; Bouée, S; Detournay, B; Fontbonne, A; Guillausseau, PJ; Halimi, S; Nachit, F1
Abo-Warda, SM; El-Bassossy, HM; Fahmy, A1
Home, P1
Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K1
Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N1
Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM1
Viberti, GC1
Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D1
Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S1
Bosch, J; Gerstein, HC; Holman, R; Pogue, J; Yusuf, S1
Ahn, CW; Cha, BS; Choi, D; Choi, SH; Jang, Y; Kim, SK; Ko, YG; Lee, HC; Lim, SK1
Baldeweg, S; Baldi, S; Casolaro, A; Ferrannini, E; Natali, A; Sironi, AM; Toschi, E; Yudkin, JS1
Fonseca, VA; Jawa, AA1
Guan, Y; Jin, N; Mao, J; Wang, G; Wang, X; Wei, J1
Cho, L; Lewis, BE; Leya, FS; Steen, LH1
Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R1
Bošanská, L; Doležalová, R; Haluzík, M; Haluzík, MM; Kasalová, Z; Lacinová, Z; Stulc, T1
Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C1
Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A1
Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA1
Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S1
Abdul Rahman, AR; Ismail, AA; Ismail, SB; Naing, NN; Rahman, S1
Bahlmann, FH; Besler, C; Doerries, C; Drexler, H; Fliser, D; Haller, H; Horváth, T; Kirchhoff, N; Landmesser, U; Limbourg, A; Limbourg, F; Müller, M; Schulz, S; Sorrentino, SA1
Hanefeld, M1
Chin-Dusting, J; Cooper, ME; Jandeleit-Dahm, KA; Kling, D; Mizrahi, J; Murphy, A; Sebokova, E; Sheehy, K; Tikellis, C; Woollard, KJ1
Honisett, SY; Komesaroff, PA; Stojanovska, L1
Bégaud, B; Bernard, MH; Eschwège, E; Grimaldi, A; Oppert, JM; Pouchain, D; Slama, G1
Alevizos, M; Angelopoulou, N; Iliadis, F; Kadoglou, NP; Liapis, CD; Perrea, D1
Bauersachs, J; Thum, T1
Chilton, R; Sulistio, MS; Thukral, N; Zion, A1
Matthews, DR1

Reviews

14 review(s) available for rosiglitazone and Diabetic Angiopathies

ArticleYear
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Diabetes/metabolism research and reviews, 2009, Volume: 25, Issue:2

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases

2009
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome

2009
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    International journal of clinical practice, 2009, Volume: 63, Issue:9

    Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance

2009
Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:12

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones

2010
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
    Annales d'endocrinologie, 2010, Volume: 71, Issue:6

    Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones

2010
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11

    Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome

2012
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Diabetes technology & therapeutics, 2012, Volume: 14 Suppl 1

    Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom

2012
Rosiglitazone: potential beneficial impact on cardiovascular disease.
    International journal of clinical practice, 2003, Volume: 57, Issue:2

    Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones

2003
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
    Cardiology clinics, 2005, Volume: 23, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Fibrinolysis; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Postprandial Period; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Troglitazone

2005
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:4

    Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones

2006
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
    Blood pressure, 2006, Volume: 15, Issue:5

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Humans; Premedication; Ramipril; Rosiglitazone; Thiazolidinediones; Treatment Outcome

2006
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
    Cardiovascular diabetology, 2007, Aug-15, Volume: 6

    Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones

2007
The anti-atherogenic effects of thiazolidinediones.
    Current diabetes reviews, 2007, Volume: 3, Issue:1

    Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones

2007
PPARgamma agonists and coronary atherosclerosis.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides

2008

Trials

20 trial(s) available for rosiglitazone and Diabetic Angiopathies

ArticleYear
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
    Pediatric diabetes, 2020, Volume: 21, Issue:6

    Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone

2020
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
    Diabetes care, 2014, Volume: 37, Issue:3

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium-Binding Proteins; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Up-Regulation

2014
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
    Journal of obesity, 2015, Volume: 2015

    Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin

2015
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
    American heart journal, 2008, Volume: 156, Issue:6

    Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional

2008
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans

2009
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.
    Diabetes & vascular disease research, 2009, Volume: 6, Issue:1

    Topics: Adult; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise Test; Fibrinolytic Agents; Heart; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Reproducibility of Results; Research Design; Rosiglitazone; Thiazolidinediones; Triglycerides; Young Adult

2009
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
    American heart journal, 2009, Volume: 157, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents

2009
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
    European heart journal, 2010, Volume: 31, Issue:18

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Exercise Test; Female; Humans; Hypoglycemic Agents; Magnetic Resonance Angiography; Male; Middle Aged; Oxygen Consumption; Plasma Volume; Rosiglitazone; Stroke Volume; Thiazolidinediones; Treatment Outcome

2010
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
    The international journal of cardiovascular imaging, 2012, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional

2012
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Circulation, 2002, Aug-06, Volume: 106, Issue:6

    Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors

2002
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
    Journal of human hypertension, 2003, Volume: 17, Issue:1

    Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome

2003
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
    American heart journal, 2004, Volume: 147, Issue:5

    Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones

2004
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
    Diabetologia, 2004, Volume: 47, Issue:9

    Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Body Size; Diabetes Mellitus; Diabetes, Gestational; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Life Style; Male; Middle Aged; Patient Selection; Pregnancy; Ramipril; Rosiglitazone; Thiazolidinediones

2004
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
    Diabetes care, 2004, Volume: 27, Issue:11

    Topics: Adult; Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome; Vasodilator Agents

2004
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
    European heart journal, 2005, Volume: 26, Issue:5

    Topics: Acetylcholine; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Hematocrit; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vasodilation; Vasodilator Agents

2005
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
    Metabolism: clinical and experimental, 2005, Volume: 54, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Chemokine CCL2; Chemokines; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Inflammation; Lipopolysaccharides; Male; Middle Aged; Monocytes; PPAR gamma; Rosiglitazone; Thiazolidinediones

2005
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Journal of internal medicine, 2007, Volume: 261, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima

2007
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    American heart journal, 2007, Volume: 153, Issue:3

    Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents

2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
    European journal of clinical pharmacology, 2007, Volume: 63, Issue:8

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arteries; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Middle Aged; Pulsatile Flow; Ramipril; Rosiglitazone; Stroke Volume; Thiazolidinediones; Vascular Diseases

2007
Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 2008, Volume: 25, Issue:3

    Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise; Female; Humans; Hypoglycemic Agents; Male; Metalloproteases; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones

2008

Other Studies

28 other study(ies) available for rosiglitazone and Diabetic Angiopathies

ArticleYear
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Animals; Aorta, Abdominal; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression; Humans; Hypoglycemic Agents; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phytotherapy; Rosiglitazone; Signal Transduction

2018
US regulators relax restrictions on rosiglitazone.
    BMJ (Clinical research ed.), 2013, Nov-28, Volume: 347

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration

2013
A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:8

    Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones

2008
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:1

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome

2009
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Acta diabetologica, 2009, Volume: 46, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones

2009
Rosiglitazone is associated with mortality in chronic hemodialysis patients.
    Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:5

    Topics: Aged; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Female; Hospitalization; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Rosiglitazone; Thiazolidinediones

2009
Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Journal of the Indian Medical Association, 2008, Volume: 106, Issue:11

    Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome

2008
Rosiglitazone.
    Primary care diabetes, 2009, Volume: 3, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Europe; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States

2009
Rosiglitazone and pioglitazone. Beware macular oedema.
    BMJ (Clinical research ed.), 2009, Sep-22, Volume: 339

    Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular Edema; Pioglitazone; Rosiglitazone; Thiazolidinediones

2009
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones

2009
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.
    Cardiovascular diabetology, 2010, May-19, Volume: 9

    Topics: Adiposity; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Femoral Artery; Hypoglycemic Agents; Matrix Metalloproteinase 9; Myography; Nitric Oxide Synthase Type III; Pancreatic Elastase; Rats; Rats, Zucker; Receptors, Adrenergic, alpha; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents

2010
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
    Journal of diabetes, 2009, Volume: 1, Issue:4

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Rosiglitazone; Thiazolidinediones

2009
A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.
    Diabetes & metabolism, 2012, Volume: 38, Issue:4

    Topics: Adult; Aged; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; France; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Rosiglitazone; Smoking; Surveys and Questionnaires; Thiazolidinediones; Time Factors; Treatment Outcome

2012
Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
    Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:8

    Topics: Animals; Blood Glucose; Blood Pressure; Blood Vessels; Calcium; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Male; Nitric Oxide; Potassium Chloride; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides

2012
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
    Diabetes, obesity & metabolism, 2003, Volume: 5, Issue:1

    Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides

2003
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
    MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones

2003
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschritte der Medizin, 2003, Sep-18, Volume: 145, Issue:38

    Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Survival Rate; Thiazolidinediones

2003
Diabetes drug may also benefit blood vessels.
    Mayo Clinic health letter (English ed.), 2003, Volume: 21, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones

2003
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:7

    Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones

2004
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
    Cardiology, 2005, Volume: 104, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Rosiglitazone; Stents; Survival Rate; Thiazolidinediones

2005
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
    Physiological research, 2007, Volume: 56, Issue:6

    Topics: Adipose Tissue; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; E-Selectin; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Adhesion Molecule-1; Lipids; Matrix Metalloproteinase 9; Middle Aged; Peroxidase; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1

2007
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
    Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:1

    Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones

2007
Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Circulation, 2007, Jul-10, Volume: 116, Issue:2

    Topics: Aged; Animals; Blood Pressure; Carotid Arteries; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Endothelium, Vascular; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Nitric Oxide; Oxidative Stress; PPAR gamma; Reference Values; Rosiglitazone; Stem Cells; Superoxides; Thiazolidinediones; Vasodilator Agents

2007
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
    Atherosclerosis, 2008, Volume: 199, Issue:1

    Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis

2008
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].
    Annales d'endocrinologie, 2008, Volume: 69, Issue:1

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors

2008
Letter by Thum et al regarding article, "Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist
    Circulation, 2008, Mar-11, Volume: 117, Issue:10

    Topics: Biopterins; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Humans; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; PPAR gamma; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents

2008
Guidance on rosiglitazone for type 2 diabetes mellitus.
    Lancet (London, England), 2001, Feb-10, Volume: 357, Issue:9254

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; England; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones

2001
[Infarct prevention for diabetics. To lower blood sugar is not enough].
    MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents

2001